Core Cap Advisors, LLC Cullinan Oncology, Inc. Transaction History
Core Cap Advisors, LLC
- $2.18 Billion
- Q1 2025
A detailed history of Core Cap Advisors, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 29 shares of CGEM stock, worth $250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29Holding current value
$250% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$66.2 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.7 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33.4 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.5 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $395M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...